Sanofi

News

Sanofi spin-off EuroAPI slumps as revenues falter

Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.

News

Sanofi buys into Teva’s anti-TL1A therapy for IBD

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva

News

Sanofi partners J&J on E. coli vaccine

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus

News

CDC backs maternal use of Pfizer’s RSV vaccine

The way has been largely cleared for the rollout of Pfizer’s respiratory syncytial virus (RSV) vaccine to help protect newborns and infants from the virus after an advisor

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

Digital

Biopharma’s rapid transition to omnichannel marketing

The COVID-19 pandemic accelerated a change that was already underway with regards to the digitisation of biopharma marketing – and the increasing ubiquity of omnichannel.

Sanofi spin-off EuroAPI slumps as revenues falter

Sanofi buys into Teva’s anti-TL1A therapy for IBD

Sanofi partners J&J on E. coli vaccine

CDC backs maternal use of Pfizer’s RSV vaccine

CHMP backs Almirall’s eczema therapy lebrikizumab

Biopharma’s rapid transition to omnichannel marketing

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks